We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -7.00 | -0.51% | 1,356.50 | 1,356.00 | 1,356.50 | 1,370.00 | 1,353.00 | 1,365.00 | 5,013,886 | 16:29:58 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.41 | 56.52B |
From Jan 2020 to Jan 2025
By Stephen Nakrosis
Alector Inc. shares touched a 52-week high Friday after the biotechnology company said it would collaborate with GlaxoSmithKline PLC to develop and commercialize antibodies for neurodegenerative diseases.
Alector is set to receive $700 million in upfront payments and up to $1.5 billion in potential milestone payments, profit sharing and royalties from the deal, the company said.
At 11:16 a.m. ET, shares of Alector were trading 71% higher at $38.39. Volume at the time topped 20.8 million shares, above the stock's 65-day average volume of 590,484.
Earlier in the session, Alector's stock reached a 52-week high of $43.32 a share.
-Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 02, 2021 11:36 ET (15:36 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
